United-Guardian (UG) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 declined 24% year-over-year to $2.48M, mainly due to a 63% drop in cosmetic ingredient sales from reduced orders by Ashland Specialty Ingredients, partially offset by 23% growth in pharmaceutical and 43% growth in medical lubricant sales.

• Net income for Q1 2025 was $560,895, down 39% from $925,442 in Q1 2024.

• Strategic initiatives included a new distribution agreement for the Natrajel® sexual wellness line and expanded partnerships in the UK, Ireland, and South Korea.

• The company remains focused on R&D for specialty ingredients and is positioned for future growth through product innovation and market expansion.

Financial highlights

• Net sales for Q1 2025: $2,481,127, down from $3,254,944 in Q1 2024.

• Net income for Q1 2025: $560,895 ($0.12 per share), compared to $925,442 ($0.20 per share) in Q1 2024.

• Gross margin improved as cost of sales as a percentage of net sales decreased to 45% from 48% year-over-year.

• Dividends declared and paid in Q1 2025 totaled $1,607,893 ($0.35 per share), up from $1,148,468 ($0.25 per share) in Q1 2024.

• Other income (investment and securities): $97,037 in Q1 2025, down from $139,569 in Q1 2024.

Outlook and guidance

• Management anticipates initial sales of the Natrajel® line in 2025, targeting growth in the sexual wellness segment.

• The company expects its effective tax rate to remain at 21% for the current fiscal year.

• Working capital and liquidity are considered sufficient to support operations for at least the next twelve months.

• Management notes uncertainty regarding the impact of new U.S. tariffs on imports, making it difficult to predict future operational or financial effects.

• Ashland Specialty Ingredients confirmed no significant loss of business or customers, attributing order reduction to excess inventory and timing.